Alingasa, Relmar C.
HRN: 22-64-33 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/24/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/24/2023
03/03/2023
I
4.5gram
Q6hr
CAP-MR; T/C Immunocompromised State
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes